Gheorghe Liana, Iacob Speranta, Simionov Iulia, Vadan Roxana, Gheorghe Cristian, Iacob Razvan, Parvulescu Iulia, Constantinescu Ileana
Hepatology Unit, Center of Gastroenterology and Hepatology, Fundeni Clinical Institute, Str. Fundeni no. 258, 72437 Bucharest, Romania.
Rom J Gastroenterol. 2005 Dec;14(4):329-35.
The aim of this study was to define the natural long-term course of HDV compensated cirrhosis.
166 consecutive patients with compensated HDV-related cirrhosis diagnosed since 1994 were followed up until the first decompensation and then until death, liver transplantation or 31st of December 2004. The survival during follow-up and the survival according to the type of first decompensation were calculated using the Kaplan Meier method. Survival curves were compared using the log-rank test.
56 females (33.7%) and 110 males (66.3%) with a mean age of 40.7+/-7.9 years were included in the study. The mean Child Pugh and MELD score at the first episode of hepatic decompensation was 8.6+/-2.08 and 15.19+/-5.42, respectively. The median survival was 58.3 months since the diagnosis of compensated cirrhosis and the mean time to first decompensation was 21+/-19 months. The probability of survival after the diagnosis of compensated cirrhosis was 94.3%, 82.5%, and 51.5% at 1, 2, and 5 years, respectively. Ascites was the most frequent first decompensation (80.7%), followed by jaundice (30.1%), portal hypertensive gastrointestinal bleeding (PHGIB) (28.9%), hepatic encephalopathy (HE) (12%), hepatocellular carcinoma (HCC) (12%), portal vein thrombosis (8.4%), spontaneous bacterial peritonitis (SBP), hepatorenal syndrome. 86 patients (51.8%) presented more than one complication at initial decompensation. Survival was worse in patients with jaundice and SBP (p=0.001), followed by patients with HE (p=0.05) and patients who presented more than one initial complication (p=0.03). In the multivariate survival analysis only PHGIB as first decompensation and MELD score>15 were independent predictors of death.
HDV-related cirrhosis in Romania is an aggressive disease with a median time to decompensation less than 2 years and a median survival less than 5 years. Jaundice, the main clinical consequences of portal hypertension and HCC are the most frequent causes of decompensation and more than half the patients present two or more concomitant initial complications.
本研究旨在明确丁型肝炎病毒(HDV)代偿期肝硬化的自然长期病程。
对1994年以来确诊的166例连续性HDV相关代偿期肝硬化患者进行随访,直至首次失代偿,然后直至死亡、肝移植或2004年12月31日。采用Kaplan-Meier法计算随访期间的生存率以及根据首次失代偿类型的生存率。使用对数秩检验比较生存曲线。
本研究纳入了56例女性(33.7%)和110例男性(66.3%),平均年龄为40.7±7.9岁。首次肝失代偿时的平均Child-Pugh评分和终末期肝病模型(MELD)评分分别为8.6±2.08和15.19±5.42。自代偿期肝硬化诊断后的中位生存期为58.3个月,首次失代偿的平均时间为21±19个月。代偿期肝硬化诊断后的1年、2年和5年生存率分别为94.3%、82.5%和51.5%。腹水是最常见的首次失代偿类型(80.7%),其次是黄疸(30.1%)、门静脉高压性胃肠道出血(PHGIB)(28.9%)、肝性脑病(HE)(12%)、肝细胞癌(HCC)(12%)、门静脉血栓形成(8.4%)、自发性细菌性腹膜炎(SBP)、肝肾综合征。86例患者(51.8%)在初次失代偿时出现了一种以上的并发症。黄疸和SBP患者的生存率较差(p=0.001),其次是HE患者(p=0.05)和初次出现一种以上并发症的患者(p=0.03)。在多因素生存分析中,仅PHGIB作为首次失代偿和MELD评分>15是死亡的独立预测因素。
罗马尼亚的HDV相关肝硬化是一种侵袭性疾病,失代偿的中位时间少于2年,中位生存期少于5年。黄疸、门静脉高压和HCC的主要临床后果是最常见的失代偿原因,超过一半的患者同时出现两种或更多的初始并发症。